Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 259-265

  Kano, Osamu ^a   Ito, Hirono ^a   Takazawa, Takanori ^a   Kawase, Yuji ^a   Murata, Kiyoko ^a   Iwamoto, Konosuke ^a   Nagaoka, Tetsuro ^a   Hirayama, Takehisa ^a   Miura, Ken ^a   Nagata, Riya ^a   Kiyozuka, Tetsuhito ^b   Aoyagi, Jo ^b   Sato, Ryuta ^b   Eguchi, Teruo ^c   Ikeda, Ken ^a   Iwasaki, Yasuo ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^b Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^c Sakura kai Medical Group   (Japan)

Author keywords

Acetylcholinesterase inhibitors; Agitation; Alzheimer's disease; Donepezil; Galantamine; Memantine

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; COGNITION; COHEN MANSFIELD AGITATION INVENTORY; CONTROLLED STUDY; DISABILITY ASSESSMENT FOR DEMENTIA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION IMPAIRMENT SCALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRIC INVENTORY SCORE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874384161     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S40682     Document Type: Article

References (31)

1. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078-1081.
2. Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15(3):346-353.
3. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000; 54(12):2261-2268.
4. Winblad B. Maintaining functional and behavioral abilities in Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15 Suppl 1:S34-S40.
5. Samochocki M, Hoffe A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 2003;305(3): 1024-1036.
6. Reisberg B, Doody R, Stoffer A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
7. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem. 1984;42(1):1-11.
8. Shimizu E, Tang Y P, Rampon C, Tsien JZ. NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. Science. 2000;290(5494):1170-1174.
9. Edwards K, Therriault O'Connor J, Gorman C. Switching from donepezil or rivastigmine to galantamine in clinical practice. J Am Geriatr Soc. 2004;52(11):1965.
10. Engedal K, Davis B, Richarz U, Han J, Schauble B, Andreasen N. Two galantamine titration regimens in patients switched from donepezil. Acta Neurol Scand. 2012;126(1):37-44.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
12. Folstein M F, Folstein SE, McHugh PR. "Mini-mental state". A practical methodfor the clinician. J Psychiatr Res. 1975;12(3):189-198.
13. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999;53(5):471-481.
14. Homma A, Niina R, Ishii T, Hasegawa K. Development of a new rating scale for dementia in the elderly: Mental function impairment scale (MENFIS). Japanese Journal of Geriatric Psychiatry. 1991;2(10): 1217-1222.
15. Cohen-Mansfeld J, Libin A. Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation. Int J Geriatr Psychiatry. 2004;19(9):881-891.
16. Homma A, Usui M. Cohen-Mansfield Agitation Inventory (CMAI). Nihon Rinsho. 2004;62 Suppl 4:39-41. Japanese.
17. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10-S16.
18. Hirono N, Mori E, Ikejiri Y, et al. Japanese version of the Neuropsychiatric Inventory - a scoring system for neuropsychiatric disturbance in dementia patients. No to Shinkei. 1997;49(3):266-271. Japanese.
19. Schneider LS, Olin JT. Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr. 1996;8(2):277-288.
20. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157(1):4-15.
21. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004; 161(3):532-538.
22. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8): 707-714.
23. Mintzer JE, Kershaw P. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry. 2003;18(4):292-297.
24. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007; 357(14):1382-1392.
25. Matthews KL, Chen C P, Esiri MM, Keene J, Minger SL, Francis PT. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry. 2002;51(5):407-416.
26. Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine Memmdsg. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67(1): 57-63.
27. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-324.
28. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. Neuro Rx. 2004;1(1):101-110.
29. Senanarong V, Cummings JL, Fairbanks L, et al. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord. 2004;17(1-2):14-20.
30. Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofbrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol. 2001;49(3):355-361.
31. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59(11):1721-1729.